In current Dermatology practice, options for vitiligo remain limited. The purpose of this
study is to determine if once daily dosed topical rapamycin is effective for the treatment of
patients with vitiligo. Participants will apply either 0.1% topical rapamycin or 0.001%
topical rapamycin for six months to a lesion on one side of the body, and topical placebo to
a corresponding lesion on the opposite side of the body. The study also aims to evaluate
patient satisfaction and identify any adverse effects on these dosing regimens.